EnWave Announces New Significant Patent Approval

VANCOUVER, BC--(Marketwired - February 06, 2015) - EnWave Corporation (TSX VENTURE: ENW) (FRANKFURT: E4U) ("EnWave", or the "Company") is pleased to announce that the Company has been granted a significant Radiant Energy Vacuum ("REV™") dehydration technology patent in Canada. The patent protects the improved modular design of EnWave's nutraREV^® machinery, which is the most commercially advanced platform in the Company's technology portfolio. EnWave has sold or received purchase orders for five (5) nutraREV^® dehydrators based on this design in the past 10 months. The modular nutraREV^® patent has also been filed for in the United States of America and Europe.

EnWave's patent suite consists of eighteen patents that have been filed for through the international Patent Cooperation Treaty process. Thirteen of those patents have been granted, many in multiple global jurisdictions. The modular nutraREV^® patent approval further strengthens the Company's intellectual property and builds on the recent momentum generated in late 2014 from the approval of both patents protecting the method of dehydrating vaccines and patents protecting the quantaREV^® machinery design.

EnWave is continuing to pursue additional patent protection for new innovations as they arise.

About EnWave
EnWave Corporation is a Vancouver-based industrial technology company developing commercial applications for its proprietary REV™ dehydration technology. EnWave aims to sign royalty-bearing commercial licenses with leading food and pharmaceutical companies for the use of its revolutionary technology. Thus far the Company has signed twelve royalty-bearing licenses, opening up eight distinct market sectors for commercialization with companies. In addition to these licenses, EnWave has formed a Limited Liability Partnership, NutraDried LLP, to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese^® brand.

EnWave is introducing REV™ as a new dehydration standard in the food and biological material sectors: potentially faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently has three commercial REV™ platforms: nutraREV^® is used in the food industry to dry food products quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour; powderREV^® is used for the bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes below the freezing point and quantaREV^® is used for continuous, high-volume low-temperature drying. Two additional platforms, bioREV^® and freezeREV^®, are being developed as new methods to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation
Dr. Tim Durance
President, CEO and Director

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party claims referred to in this release are not guaranteed to be accurate. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.